Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Kilitch Drugs India Ltd has submitted the disclosure under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE:18-07-2011
18-07-2011
Board to consider Dividend
Kilitch Drugs India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 25, 2011, inter alia, to consider the following:1. To take on record the Audited Consolidated Financial Results of the Company for the year ended March 31, 2011;2. To recommend dividend on equity shares of the Company subject to approval of the members at the ensuing 19th Annual General Meeting;...18-07-2011
Disclosures under Reg. 3(3) of SEBI (SAST) Regulations, 1997
Paresh Mehta has submitted the disclosure under Regulation 3(3) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 1997 to BSE:08-07-2011
Disclosures under Reg. 3(3) of SEBI (SAST) Regulations, 1997
Mukund Prataprai Mehta has submitted the disclosure under Regulation 3(3) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 1997 to BSE:08-07-2011
Financial Results for Mar 31, 2011
Kilitch Drugs India Ltd has informed BSE about the Financial Results for the Period ended March 31, 2011.14-05-2011
Outcome of Board Meeting
Kilitch Drugs India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 14, 2011, inter alia, has decided the following:- To allot 15750 shares against the exercise of Employee Stock Option under ESOS KDL 2007 at a price @ Rs. 47.50. It was further decided to make an application for listing of said shares.14-02-2011
Financial Results for Dec 31, 2010
Kilitch Drugs India Ltd has informed BSE about the Financial Results for the Quarter ended December 31, 2010.14-02-2011
Board Meeting on Feb 14, 2011
Kilitch Drugs India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 14, 2011, inter alia, to transact the following:1. To take on record the Unaudited (Provisional) Financial Results for the Quarter ended December 31, 2010.2. To consider allotment of shares against exercise of employee stock option under ESOS KDL 2007 as approved by the shareholders of the Company at their Extra Ordinary General Meeting held on May 31, 2010.02-02-2011
Crisil Rating on Bank Facilities
Kilitch Drugs India Ltd has informed BSE that the Company has been awarded 'A-' rating by CRISIL for its Finance Related Facilities, which reaffirms stable status of the Company.27-12-2010